Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)

Table 2 Elimination of doxorubicin by double filtration plasmapheresis

C_max of doxorubicin post infusion	34 ± 5	[μM]
Doxorubicin at plasmapheresis onset	72 ± 6%	[% of C_max]
Doxorubicin at plasmapheresis termination	28 ± 9%	[% of C_max]
Elimination of total doxorubicin	45 ±7%	[% of total doxorubicin dose]
Elimination of doxorubicin in plasma	62 ± 9%	[% of plasma doxorubicin at plasmapheresis initiation]
Reduction in AUC	50 ± 3%

A total of 57 apheresis treatments were conducted. Treated plasma volume was 3 l, plasmapheresis was initiated~46 h after PLD infusion was terminated. Concentration of doxorubicin in plasma was measured immediately after infusion (c_max), at apheresis onset and when apheresis was terminated. The eliminated amount of total doxorubicin dosage (line 4) and of circulating liposomal doxorubicin at apheresis onset (line 5) is given. The AUC was calculated as described in methods, and the reduction in AUC of doxorubicin by apheresis is stated. Data are mean ± SD.

ISSN: 1471-2407